VIM and breast cancer: For instance, miR-17-5p directly targets vimentin in colorectal cancer [114], miR-20a inhibits EMT by suppressing TWIST1 and TGFBR2 in breast cancer [115], and miR-22 blocks Snail expression and the MAPK1/Slug/vimentin feedback loop in bladder cancer [116].